Se hai scelto di non accettare i cookie di profilazione e tracciamento, puoi aderire all’abbonamento "Consentless" a un costo molto accessibile, oppure scegliere un altro abbonamento per accedere ad ANSA.it.

Ti invitiamo a leggere le Condizioni Generali di Servizio, la Cookie Policy e l'Informativa Privacy.

Puoi leggere tutti i titoli di ANSA.it
e 10 contenuti ogni 30 giorni
a €16,99/anno

  • Servizio equivalente a quello accessibile prestando il consenso ai cookie di profilazione pubblicitaria e tracciamento
  • Durata annuale (senza rinnovo automatico)
  • Un pop-up ti avvertirà che hai raggiunto i contenuti consentiti in 30 giorni (potrai continuare a vedere tutti i titoli del sito, ma per aprire altri contenuti dovrai attendere il successivo periodo di 30 giorni)
  • Pubblicità presente ma non profilata o gestibile mediante il pannello delle preferenze
  • Iscrizione alle Newsletter tematiche curate dalle redazioni ANSA.


Per accedere senza limiti a tutti i contenuti di ANSA.it

Scegli il piano di abbonamento più adatto alle tue esigenze.

Economia

COMUNICATO STAMPA - Responsabilità editoriale di Business Wire

Altasciences Contributes to Positive Top-Line Phase 1 Results for Chronic Cough Drug Candidate

Business Wire

Altasciences recently completed an important First-in-Human (FIH), Phase I, integrated adaptive clinical trial, including single and multiple ascending doses (SAD and MAD), Project Management, Bioanalysis, and Medical Writing, for sponsor Bellus Health.

Altasciences’ contributions to the positive top-line results were significant. From recruitment of 90 subjects to management of all relevant aspects of this important FIH trial, Altasciences used a flexible and adaptive approach to fully meet the client’s needs. Altasciences’ contributions allowed Bellus Health to make a well-informed decision to proceed with their promising drug candidate for chronic cough.

We awarded this trial to Altasciences based on their reputation for quality, speed and efficiency, and we were not disappointed. Thanks to their great efforts, we have been able to determine that our compound is safe and well-tolerated, and we are proceeding to the next stage of development without delay. Altasciences’ ability to deliver results efficiently helped us make important decisions to move ahead,” says Dr. Denis Garceau, Senior Vice President, Drug Development, at Bellus Health.

Altasciences conducts hundreds of early phase clinical trials annually. Their vast participant database permits rapid recruitment, and they are constantly refining their processes and offerings to better meet sponsor needs.

We are very proud of our work on novel compounds at Altasciences, and the fact that we’re able to deliver results in a timely, efficient manner that meets or exceeds our sponsors’ drug development timelines,” says Ingrid Holmes, Vice President, Global Clinical Operations, for Altasciences.

About Altasciences

Altasciences is a mid-size contract research organization with a unique focus on supporting drug development from lead candidate selection to proof of concept. Altasciences encompasses Algorithme Pharma in Montreal, QC, Vince & Associates Clinical Research in Kansas City, KS, Algorithme Pharma USA in Fargo, ND, and Altasciences Preclinical Services in Seattle, WA. With over 25 years of industry experience, Altasciences provides preclinical and clinical solutions to an international customer base of biopharmaceutical companies. Altasciences’ full-service solutions offering in this critical stage of drug development includes preclinical safety testing, clinical pharmacology services, bioanalysis, medical writing, biostatistics, data management, and overall program management.

Julie-Ann Cabana
jcabana@altasciences.com
913 304-4505

Permalink: http://www.businesswire.com/news/home/20181212005420/en

Video Economia


Vai al sito: Who's Who

Modifica consenso Cookie